Julian H McLain, M.D.
Investigator
Julian Hardy McLain, MD is a board-certified hematologist and oncologist at Palo Alto Medical Foundation, part of Sutter Health in San Mateo, California. He completed his Hematology/Oncology fellowship and Internal Medicine residency at LAC+USC Medical Center, following his medical degree from Rosalind Franklin University Chicago Medical School. Dr. McLain holds a Bachelor of Arts in Chemistry with Honors from Lake Forest College.
Dr. McLain’s clinical and research interests include hematologic malignancies and improving care delivery in underserved populations. His work has been presented at institutional and national forums, with peer-reviewed publications in journals such as Blood, ACG Case Reports Journal, and the Journal of Cardiovascular Pharmacology and Therapeutics. He has also contributed to multiple patents in chemical engineering prior to his medical training.
Recognized for excellence in teaching and humanistic care, Dr. McLain is a member of the Gold Humanism Honor Society and recipient of the Resident Award for Outstanding Teaching.
Clinical trials
- Clinical trial
Adjuvant Grade II or III Meningioma JZP3507-202
A Phase 2 Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP3507 (ONC206) in Adults With Recurrent Grade 2 or 3 Meningioma
Status: Open to Enrollment
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Status: Open to Enrollment
- Clinical trial
Metastatic Colorectal Cancer C6461003
AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
Status: Open to Enrollment